Antithrombotic treatment of splanchnic vein thrombosis: Results of an international registry

Walter Ageno, Nicoletta Riva, Sam Schulman, Soo Mee Bang, Maria Teresa Sartori, Elvira Grandone, Jan Beyer-Westendorf, Giovanni Barillari, Matteo Nicola Dario Di Minno, Francesco Dentali

Research output: Contribution to journalArticle

Abstract

Treatment of splanchnic vein thrombosis (SVT) is a clinical challenge due to heterogeneity of clinical presentations, increased bleeding risk, and lack of evidences from clinical trials. We performed an international registry to describe current treatment strategies and factors associated with therapeutic decisions in a large prospective cohort of unselected SVT patients. A total of 613 patients were enrolled (mean age 53.1 years, standard deviation ± 14.8); 62.6% males; the majority (468 patients) had portal vein thrombosis. Most common risk factors included cirrhosis (27.8%), solid cancer (22.3%), and intra-abdominal inflammation/infection (11.7%); in 27.4% of patients, SVT was idiopathic. During the acute phase, 470 (76.7%) patients received anticoagulant drugs, 136 patients (22.2%) remained untreated. Incidental diagnosis, single vein thrombosis, gastrointestinal bleeding, thrombocytopenia, cancer, and cirrhosis were significantly associated with no anticoagulant treatment. Decision to start patients on vitamin K antagonists after an initial course of parenteral anticoagulation was significantly associated with younger age, symptomatic onset, multiple veins involvement, and unprovoked thrombosis. Although a nonnegligible proportion of SVT patients did not receive anticoagulant treatment, the majority received the same therapies recommended for patients with usual sites thrombosis, with some differences driven by the site of thrombosis and the pathogenesis of the disease.

Original languageEnglish
Pages (from-to)99-105
Number of pages7
JournalSeminars in Thrombosis and Hemostasis
Volume40
Issue number1
DOIs
Publication statusPublished - Feb 2014

Fingerprint

Viscera
Registries
Veins
Thrombosis
Anticoagulants
Therapeutics
Fibrosis
Hemorrhage
Intraabdominal Infections
Vitamin K
Portal Vein
Age of Onset
Thrombocytopenia
Neoplasms
Clinical Trials
Inflammation

Keywords

  • heparin
  • splanchnic vein thrombosis
  • vitamin K antagonist

ASJC Scopus subject areas

  • Hematology
  • Cardiology and Cardiovascular Medicine

Cite this

Antithrombotic treatment of splanchnic vein thrombosis : Results of an international registry. / Ageno, Walter; Riva, Nicoletta; Schulman, Sam; Bang, Soo Mee; Sartori, Maria Teresa; Grandone, Elvira; Beyer-Westendorf, Jan; Barillari, Giovanni; Di Minno, Matteo Nicola Dario; Dentali, Francesco.

In: Seminars in Thrombosis and Hemostasis, Vol. 40, No. 1, 02.2014, p. 99-105.

Research output: Contribution to journalArticle

Ageno, W, Riva, N, Schulman, S, Bang, SM, Sartori, MT, Grandone, E, Beyer-Westendorf, J, Barillari, G, Di Minno, MND & Dentali, F 2014, 'Antithrombotic treatment of splanchnic vein thrombosis: Results of an international registry', Seminars in Thrombosis and Hemostasis, vol. 40, no. 1, pp. 99-105. https://doi.org/10.1055/s-0033-1363473
Ageno, Walter ; Riva, Nicoletta ; Schulman, Sam ; Bang, Soo Mee ; Sartori, Maria Teresa ; Grandone, Elvira ; Beyer-Westendorf, Jan ; Barillari, Giovanni ; Di Minno, Matteo Nicola Dario ; Dentali, Francesco. / Antithrombotic treatment of splanchnic vein thrombosis : Results of an international registry. In: Seminars in Thrombosis and Hemostasis. 2014 ; Vol. 40, No. 1. pp. 99-105.
@article{d4df45105ff042e7a265bcfcfb40a1c2,
title = "Antithrombotic treatment of splanchnic vein thrombosis: Results of an international registry",
abstract = "Treatment of splanchnic vein thrombosis (SVT) is a clinical challenge due to heterogeneity of clinical presentations, increased bleeding risk, and lack of evidences from clinical trials. We performed an international registry to describe current treatment strategies and factors associated with therapeutic decisions in a large prospective cohort of unselected SVT patients. A total of 613 patients were enrolled (mean age 53.1 years, standard deviation ± 14.8); 62.6{\%} males; the majority (468 patients) had portal vein thrombosis. Most common risk factors included cirrhosis (27.8{\%}), solid cancer (22.3{\%}), and intra-abdominal inflammation/infection (11.7{\%}); in 27.4{\%} of patients, SVT was idiopathic. During the acute phase, 470 (76.7{\%}) patients received anticoagulant drugs, 136 patients (22.2{\%}) remained untreated. Incidental diagnosis, single vein thrombosis, gastrointestinal bleeding, thrombocytopenia, cancer, and cirrhosis were significantly associated with no anticoagulant treatment. Decision to start patients on vitamin K antagonists after an initial course of parenteral anticoagulation was significantly associated with younger age, symptomatic onset, multiple veins involvement, and unprovoked thrombosis. Although a nonnegligible proportion of SVT patients did not receive anticoagulant treatment, the majority received the same therapies recommended for patients with usual sites thrombosis, with some differences driven by the site of thrombosis and the pathogenesis of the disease.",
keywords = "heparin, splanchnic vein thrombosis, vitamin K antagonist",
author = "Walter Ageno and Nicoletta Riva and Sam Schulman and Bang, {Soo Mee} and Sartori, {Maria Teresa} and Elvira Grandone and Jan Beyer-Westendorf and Giovanni Barillari and {Di Minno}, {Matteo Nicola Dario} and Francesco Dentali",
year = "2014",
month = "2",
doi = "10.1055/s-0033-1363473",
language = "English",
volume = "40",
pages = "99--105",
journal = "Seminars in Thrombosis and Hemostasis",
issn = "0094-6176",
publisher = "Thieme Medical Publishers",
number = "1",

}

TY - JOUR

T1 - Antithrombotic treatment of splanchnic vein thrombosis

T2 - Results of an international registry

AU - Ageno, Walter

AU - Riva, Nicoletta

AU - Schulman, Sam

AU - Bang, Soo Mee

AU - Sartori, Maria Teresa

AU - Grandone, Elvira

AU - Beyer-Westendorf, Jan

AU - Barillari, Giovanni

AU - Di Minno, Matteo Nicola Dario

AU - Dentali, Francesco

PY - 2014/2

Y1 - 2014/2

N2 - Treatment of splanchnic vein thrombosis (SVT) is a clinical challenge due to heterogeneity of clinical presentations, increased bleeding risk, and lack of evidences from clinical trials. We performed an international registry to describe current treatment strategies and factors associated with therapeutic decisions in a large prospective cohort of unselected SVT patients. A total of 613 patients were enrolled (mean age 53.1 years, standard deviation ± 14.8); 62.6% males; the majority (468 patients) had portal vein thrombosis. Most common risk factors included cirrhosis (27.8%), solid cancer (22.3%), and intra-abdominal inflammation/infection (11.7%); in 27.4% of patients, SVT was idiopathic. During the acute phase, 470 (76.7%) patients received anticoagulant drugs, 136 patients (22.2%) remained untreated. Incidental diagnosis, single vein thrombosis, gastrointestinal bleeding, thrombocytopenia, cancer, and cirrhosis were significantly associated with no anticoagulant treatment. Decision to start patients on vitamin K antagonists after an initial course of parenteral anticoagulation was significantly associated with younger age, symptomatic onset, multiple veins involvement, and unprovoked thrombosis. Although a nonnegligible proportion of SVT patients did not receive anticoagulant treatment, the majority received the same therapies recommended for patients with usual sites thrombosis, with some differences driven by the site of thrombosis and the pathogenesis of the disease.

AB - Treatment of splanchnic vein thrombosis (SVT) is a clinical challenge due to heterogeneity of clinical presentations, increased bleeding risk, and lack of evidences from clinical trials. We performed an international registry to describe current treatment strategies and factors associated with therapeutic decisions in a large prospective cohort of unselected SVT patients. A total of 613 patients were enrolled (mean age 53.1 years, standard deviation ± 14.8); 62.6% males; the majority (468 patients) had portal vein thrombosis. Most common risk factors included cirrhosis (27.8%), solid cancer (22.3%), and intra-abdominal inflammation/infection (11.7%); in 27.4% of patients, SVT was idiopathic. During the acute phase, 470 (76.7%) patients received anticoagulant drugs, 136 patients (22.2%) remained untreated. Incidental diagnosis, single vein thrombosis, gastrointestinal bleeding, thrombocytopenia, cancer, and cirrhosis were significantly associated with no anticoagulant treatment. Decision to start patients on vitamin K antagonists after an initial course of parenteral anticoagulation was significantly associated with younger age, symptomatic onset, multiple veins involvement, and unprovoked thrombosis. Although a nonnegligible proportion of SVT patients did not receive anticoagulant treatment, the majority received the same therapies recommended for patients with usual sites thrombosis, with some differences driven by the site of thrombosis and the pathogenesis of the disease.

KW - heparin

KW - splanchnic vein thrombosis

KW - vitamin K antagonist

UR - http://www.scopus.com/inward/record.url?scp=84893665292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893665292&partnerID=8YFLogxK

U2 - 10.1055/s-0033-1363473

DO - 10.1055/s-0033-1363473

M3 - Article

C2 - 24381147

AN - SCOPUS:84893665292

VL - 40

SP - 99

EP - 105

JO - Seminars in Thrombosis and Hemostasis

JF - Seminars in Thrombosis and Hemostasis

SN - 0094-6176

IS - 1

ER -